Zhejiang East-Asia Pharmaceutical (SH:605177)2026-01-22 07:55Financial Performance Expectations - The company expects a net profit attributable to shareholders for 2025 to be between -90 million and -75 million yuan[4]. - The expected net profit attributable to shareholders, excluding non-recurring gains and losses, is projected to be between -102 million and -87 million yuan[4]. - In the previous year, the net profit attributable to shareholders was -100.66 million yuan, with a total profit of -118.17 million yuan[7]. Revenue and Profit Decline Factors - The decline in revenue is attributed to factors such as domestic price reductions, industry policies, and increased market competition, leading to a decrease in gross profit of approximately 108 million yuan[8]. - Fixed asset depreciation and increased interest expenses from bank loans are expected to impact the company's performance by around 32 million yuan[8]. - The company plans to recognize an inventory impairment provision of approximately 35 million yuan due to expected declines in the net realizable value of certain inventories[8]. Strategic Direction and Management Confidence - The company is committed to an integrated strategy for active pharmaceutical ingredients and formulations to navigate the complex pharmaceutical environment[9]. - Management remains confident in the company's future development and aims to improve operational quality and product competitiveness[10]. Financial Reporting and Risks - The financial data provided is preliminary and has not yet been audited by a registered accountant[11]. - Investors are advised to pay attention to investment risks as the final financial data will be disclosed in the official 2025 annual report[12].